Anti-asthmatic effects of interleukin-1 receptor antagonist in sensitized guineaPigs

Abstract

Abstract: AIM: To observe the anti-asthmatic effects of interleukin-1 receptor antagonist (IL-1ra)in sensitized guineaPigs.METHODS: Sensitized guineaPigs were made by ovalbumin,and the tension and contraction of tracheal smooth muscles were measured by force-displacement transducer and MedLab software.RESULTS: In the doses of 0.33 -9.0 mg·kg^-1,IL-1raProlonged the asthmatic incubationPeriod and reduced animal tumble ratio in asthma guineaPigs induced by histamine-acetylcholine or ovalbumin.These effects were dose-dependent.In vitro,IL-1ra could directly relax tracheal smooth muscles uPthe dose of 3×; 10^-7mol·L^-1and the EC50 value was 5.88×; 10^-7mol·L^-1.IL-1ra antagonized the increase of trachea tension stimulated by ovalbumin at the dose of 10^-7mol·L^-1.Moreover,IL-1raPrevented tracheal smooth muscle contraction induced by ovalbumin uPthe dose of 3×; 10^-7mol·L^-1,and the IC₅₀value was 4.48×; 10^-7mol·L^-1.CONCLUSIONS: IL-1ra can directly relax tracheal smooth muscles in sensitized guineaPigs,and antagonize asthma caused by many kinds of antigens.;

Key words: pharmacology, interleukin-1, receptor antagonist, histamine, acetylcholine, asthma, contraction, guineaPigs

CLC Number:

R965.1

ZHANG Hong-Quan, XU Zheng-Xin, GE Xiao-Qun, LI Ji-Ping, SUN Yun, LIU LI. Anti-asthmatic effects of interleukin-1 receptor antagonist in sensitized guineaPigs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(5): 506-510.

References

1 Peter JB.Cytokine modulators as novel therapies for asthma[J].Annu RevPharmacol Toxicol,2002;42:81-98
2 Hakonarson H,Halapi E,Whelan R.Association between IL-1beta TNF-alpha-induced glucocorticoid-sensitive changes in multiple gene expression and altered responsiveness in airway smooth muscle[J].Am J Respir CellMol Boil,2002;25:761-71
3 Amici DM,Puggioni F,Casalil.Variations in serumlevels of interleukin(Il)-1beta,Il-2,Il-6,and tumor necrosis factor-alpha during specific immunotherapy[J].Ann Allergy Asthma Immunol,2001;86:311-3
4 Tillie-Leblond I,Pugin J,Marquette CH.Balance betweenProinflammatory cytokines and their inhibitors in bronchiallavage fromPatients with status asthmaticus[J].Am J Reapir Crit Care Med,1999;159:487-94
5 Mao XQ,Kawai M,Yamashita T.ImbalanceProduction between interleukin-1 bata(IL-1 beta)and IL-1 receptor antagonist(IL-1ra)in bronchial asthma[J].Biochem Biophys Res Commun,2000;276:607-12
6 RosenwasserlJ.New immunopharmacologic approaches to asthma:role of cytokine antagonism[J].J Allergy Clin Immunol,2000;105:S586-91
7 Ricci M,Matucci A,Rossi O.New advances in thePathogenesis and therapy of bronchial asthma[J].Ann Ital Med Int,1998;13:93-110
8 Hagaman DD,Okayama Y,D' Ambrosio C.Secretion of interleukin-1 receptor antagonist from human mast cells after immunoglobulin E-mediated activation and after segmental antigen challenge[J].Am J Respir Cell Mol boil,2001;25:685-91
9 Bjornsdottir US,Cypcar DM.Asthma:an inflammatory mediator soup[J].Allergy,1999;54:55-61
10 StassenM,Arnold M,Hultnerl,et al.Murine bone marrowderived mast cells asPotentProducers of IL-9:costimulatory function of IL-1 0 and kitligand in thePresence of IL-1[J].J Immunol,2000;164:5549-55
11 Arima M,Plitt J,Stellato C,et al.Expression of interleukin-16 by human epithelial cells[J].Am J Respir Cell Mol Biol,1999;21:684-92
12 Koyama S,Sato E,Masubuchi T,et al.Procaterol inhibits IL-1 beta-andTNF-alpha-mediated epithelial cell eosinophil chemotactic activity[J].Eur Respir J,1999;14:767-75
13 Tillieleblond I,Pugin J,Marquette CH,et al.Balance betweenProinflammatory cytokines and their inhibitors in bronchiallavage fromPatients with status asthmaticus[J].Am J Respir Crit Care Med,1999;159:487-94
14 Haffar O,Hamid Q,RenziPM.Constitutive and cytokinestimulated expression of eotaxin by human airway smooth muscle cells[J].Am J Respir Crit Care Med,1999;159:1933-42
15 Im TC,Hilsmeier KA,ReecelM.Interleukin-1 receptor antagonistProtein inhibits the synthesis of IgE andProinflammatory cytokines by allergen-stimulated mononuclear cells[J].Am J Respir Cell Mol Biol,1994;11:473-9
16 Chong BT,Agrawal DK,Romero FA.An in vivo model of beta-adrenoceptor desensitization[J].JPharmacol Toxicol Methods,1998;40:109-15
17Pangl,Holland E,Knox AJ.Role of cyclo-oxygenase-2 induction in interleukin-1 beta induced attenuation of cultured human airway smooth muscle cell cyclic AMPgeneration in response to isoprenaline[J].Br JPhamacol,1998;125:1320-8
18 BarnesPJ.Anti-inflammatory actions of glucocorticoids:molecular mechanisms[J].Clin Sci(Lond)1998;94:557-72
19 Van der Velden VH,Naber BA,Van der SpoelP.Cytokines and glucocorticoids modulate human bronchial epithelial cellPeptidases[J].Cytokine,1998;10:55-65
20levine SJ,Benfield T,Shelhamer JH.Corticosteroids induce intracellular interleukin-1 receptor antagonist type I Expression by a human airway epithelial cellline[J].Am J Respir Cell Mol Biol,1996;15:245-51

[1]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[2]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[3]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[4]	CAO Fang, QIN Kairong, ZHENG Guoshuang, ZHAO Dewei. Exploring the intervention mechanism of Ginkgo biloba for steroid-induced necrosis of the femoral head based on network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 266-275.
[5]	MA Guangli, ZHANG Jing. Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
[6]	HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang. Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
[7]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[8]	CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
[9]	GAO Lili, WANG Yuzhu, WANG Yan, LI Jian, WANG Jun. General considerations for clinical pharmacology of antitumor antibody-conjugated drugs: Implications from FDA review cases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 75-85.
[10]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[11]	LIU Yanzhi, WANG Yan, LIU Kaili, ZHOU Wenhua, ZHU Ping, WANG Yingli, DU Shouying. Inhibition and mechanism of Xihuang pill on mice bearing hepatoma H22 tumor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 754-761.
[12]	YAO Qian, CHEN Yun, SHANG Juan, XI Xiaoyun, CHEN Ying, GU Xiao, JU Wenzheng, ZOU Jiandong, LU Su, XU Meijuan. Investigation of potential pharmacodynamic substances and mechanism of Qingxin-zishen prescription decoction in treatment of menopause syndrome based on HPLC-Q-TOF-MS/MS and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 481-497.
[13]	ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang. Application of chronopharmacology in the hypertension treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.
[14]	CHENG Kuan. New progress in research and application of fenneridone [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 450-456.
[15]	XIE Mengdie, WANG Chenchen, LI Bingtao, OUYANG Changsheng, QIU Yumei, LI Hongming, TU Jun, SHANG Guangbin, TANG Xilan. Analysis on mechanism of frankincense volatile oil in prevention and treatment of cardiac hypertrophy based on in vitro cell experiment and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 241-252.